Immunogenicity of an Inactivated Split Influenza Vaccine in Institutionalized Elderly Patients

Hoecke, C. Van; Príkazský, V.; Ütö, I.; Menschikowski, C.

doi:10.1159/000213792

Cited by 31 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with recent data of Van Hoeke et al [11], the HI antibody postvaccination response of institutionalized subjects quantitatively exceeded the requirements of the European Commission for Influenza Vaccines for adults over 60 years [12], i.e., MFI of GMT 12, seroprotection 160%, and seroconversion rate 130% (table 2). Indeed, the MFI values ranged from 3.4 to 5.5, seroprotection from 70 to 84%, and positive responses from 58 to 69%.…”

Section: Discussionsupporting

confidence: 89%

Antibody Response to 1995–1996 Influenza Vaccine in Institutionalized and Non-Institutionalized Elderly Women

Iorio

Alatri²,

Camilloni³

et al. 1998

Gerontology

View full text Add to dashboard Cite

Background: Concern about poor responsiveness to influenza vaccination by institutionalized elderly people. Objective: To determine whether institutionalized elderly volunteers develop a significant antibody response following influenza vaccine and to compare this response with that of non-institutionalized subjects. Methods: The haemagglutination-inhibiting antibody response after 1995–1996 influenza vaccination [A/Shangdong/9/93 (H3N2), A/Taiwan/1/86 (H1N1), B/Panama/45/90] was estimated in 80 elderly women living in a nursing home and compared with that of 51 non-institutionalized women. Results: No differences were found in the prevaccination status, and, after vaccination, a significant humoral response was elicited both in institutionalized and non-institutionalized elderly subjects against all three influenza strains tested. The immune response of institutionalized patients was satisfactory and significantly higher than that observed in non-institutionalized women. These results were confirmed both by a separate analysis of homogeneous subgroups stratified according to the presence in the two cohorts of potential causes of differential antibody response (prevaccination antibody titre, age, long-term drug treatment, risk factors for influenza infection, and physical disability) and by logistic regression analysis in order to adjust immune responses for the different variables. Conclusion: Influenza vaccination is effective in elderly people living in nursing homes. However, the postvaccination antibody response to influenza vaccine is influenced by different factors directly or indirectly related to residence.

show abstract

Section: Discussionsupporting

confidence: 89%

Antibody Response to 1995–1996 Influenza Vaccine in Institutionalized and Non-Institutionalized Elderly Women

Iorio

Alatri²,

Camilloni³

et al. 1998

Gerontology

View full text Add to dashboard Cite

show abstract

“…We identified 60 eligible articles published between 1987 and 2006 describing inactivated seasonal influenza vaccine immunogenicity studies conducted in the United States, Canada, Europe, Israel, and Russia 10 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 . We included 129 independent study arms of which 119 reported data on response to A/H1N1, 109 on influenza B, and 108 on A/H3N2 vaccine strains (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Seidman

Richard

Viboud

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

Please cite this paper as: Seidman et al. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6(1), 52–62. Background Seasonal influenza epidemics are associated with significant morbidity and mortality each year, particularly amongst young children and the elderly. Seasonal influenza vaccines have been available for decades, yet influenza remains a major public health threat in the US, sparking interest in studies evaluating the effectiveness of vaccination. Objectives We sought to identify determinants of serological responses to inactivated seasonal influenza vaccines including number of doses, adjuvant, and subject characteristics. Methods We reviewed 60 articles published between 1987 and 2006. We used weighted multiple logistic regression and random‐effects models to evaluate how seroconversion and seroprotection rates varied with host and vaccine factors. Results Both children and seniors tended to have poorer immune responses compared to adults whereas use of adjuvant and a second vaccine dose tended to improve immune response. Pre‐vaccination serological status had a large impact on the immune response to vaccination. We found substantial heterogeneity among studies, even with similar population settings and vaccination regimen. Conclusions Future studies should stratify their results by pre‐vaccination serological status in an effort to produce more precise summary estimates of vaccine response.

show abstract

“…Amongst the 14 studies included in this review, 8 reported seroprotection rates (Ruf et al, 2004;MacKenzie, 1977;Peters et al, 1988;Delafuente et al, 1998;Buxton et al, 2001;Brydak et al, 2003;Praditsuwan et al, 2005;Hui et al, 2006) and 6 seroconversion rates alone (McElhaney et al, 1993;Powers et al, 1995;Van Hoecke et al, 1996;Minutello et al, 1999;Mysliwska et al, 2004;Keylock et al, 2007). Seroprotection rates according to CPMP criteria (Table 1) were maintained ≥4 months after influenza immunization in all 8 for A/H3N2 com-ponent and in 5 of 7 studies for the A/H1N1 and B components.…”

Section: Is the Protective Hai Titre Decline Throughout The Influenzamentioning

confidence: 90%

“…In determining whether serological CPMP criteria were met at season's end, seroprotection rates of 70-100% were maintained not just at 4 months (Delafuente et al, 1998;Buxton et al, 2001) but also at 5 months (Peters et al, 1988;Brydak et al, 2003) and, even at >6 months (Ruf et al, 2004;MacKenzie, 1977;Praditsuwan et al, 2005;Hui et al, 2006) for the A/H3N2 and A/H1N1 vaccine components. In 2 of 6 studies reporting seroconversion alone, criteria were still met at 4 months (Van Hoecke et al, 1996;Mysliwska et al, 2004). Six studies had compared antibody persistence regarding the age with no significant difference between groups (3 compared elderly with young adults (MacKenzie, 1977;Brydak et al, 2003;McElhaney et al, 1993) and 3 compared aged individuals by advancing age (Peters et al, 1988;Praditsuwan et al, 2005;Van Hoecke et al, 1996)).…”

Section: Is the Protective Hai Titre Decline Throughout The Influenzamentioning

confidence: 99%

“…In 2 of 6 studies reporting seroconversion alone, criteria were still met at 4 months (Van Hoecke et al, 1996;Mysliwska et al, 2004). Six studies had compared antibody persistence regarding the age with no significant difference between groups (3 compared elderly with young adults (MacKenzie, 1977;Brydak et al, 2003;McElhaney et al, 1993) and 3 compared aged individuals by advancing age (Peters et al, 1988;Praditsuwan et al, 2005;Van Hoecke et al, 1996)). …”

Section: Is the Protective Hai Titre Decline Throughout The Influenzamentioning

confidence: 99%

See 1 more Smart Citation

Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

Lang

Govind

Mitchell

et al. 2011

Ageing Research Reviews

View full text Add to dashboard Cite

a b s t r a c tVaccination policies in most high-income countries attempt to reduce the adverse impact of influenza targeting people aged at least 60 years. However, while it is widely believed that the current immunization strategy saves many lives, influenza infection still remains a severe burden in aged individuals leading to a wide debate on the exact magnitude of the benefit of vaccination in this population. The first aim of the present review is to examine how effective current influenza-vaccine strategies are in aged adults, by analysing which are the most important factors modulating the interpretation of study results in this population. Furthermore, consideration will be given to how immune factors influence the measurement of vaccine efficacy/effectiveness, where advancing age leads to deleterious changes in the adaptive immune system, resulting in less than optimal responses to infectious agents and vaccination. Finally this review concludes with possible strategies to improve the ability of the senescent immune system to respond to vaccination.

show abstract

Immunogenicity of an Inactivated Split Influenza Vaccine in Institutionalized Elderly Patients

Cited by 31 publications

References 0 publications

Antibody Response to 1995–1996 Influenza Vaccine in Institutionalized and Non-Institutionalized Elderly Women

Antibody Response to 1995–1996 Influenza Vaccine in Institutionalized and Non-Institutionalized Elderly Women

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

Contact Info

Product

Resources

About